Effects of sitagliptin on implant osseointegration in diabetic and non-diabetic rats

Abstract

Diabetes mellitus is an epidemic disease, and by 2025, the number of diabetic individuals could reach 300 million worldwide. Given the importance of this disease, new drugs have been developed to control blood glucose levels. Among them, there are agonists of the glucagon-likepeptide1 (GLP-1) and inhibitors of dipeptidyl peptidase-4 (DPP-4). It was discovered, however, that such drugs have other characteristics besides glucose control, such as stimulation of the formation and inhibition of bone resorption and anti-inflammatory characteristics. This study aims to evaluate the effects of sitagliptin (an DPP-4 inhibitor) on implant osseointegration in diabetic and non-diabetic rats. Forty rats will receive a titanium implant in the right tibia four weeks after induction of diabetes. Animals will be divided into 4 groups: Diabetic group treated with sitagliptin (GDS-10 mg / kg / day); Diabetic group (GD); Normoglycemic group treated with sitagliptin (GNS-10 mg / kg / day); and Normoglycemic group (GN). For induction of diabetes, the animals will receive 10% fructose solution in drinking water for 14 days and injection of streptozocin. The animals will be sacrificed 4 weeks after implant placement, when the tibia will be removed and decalcified. Bone area around the implants and linear extent of bone-implant contact surface will be evaluated with the aid of an image analysis software. The most appropriate statistical test will be selected for comparison between groups.